IVIG & Cancer Risk: CIDP Patients See Potential Benefit
- intravenous immunoglobulin, or IVIG, a common treatment for autoimmune and neurological conditions, may also reduce cancer risk, according too a new study in Frontiers.
- IVIG is a well-established treatment for various autoimmune diseases, neurologic diseases, infections and immunodeficiencies.
- Previous research hinted at IVIG's antineoplastic effects through its influence on IL-12 and NK cell activity.
Discover the groundbreaking link between IVIG therapy and reduced cancer risk. New research suggests that intravenous immunoglobulin (IVIG),primarily used to treat autoimmune and neurological conditions like CIDP,could also offer a protective effect against cancer in certain patient groups. The study, highlighted on News Directory 3, focuses on myasthenia gravis (MG) and CIDP patients, revealing promising insights into the potential antineoplastic properties of IVIG. This finding challenges existing understanding of IVIG’s role, opening avenues for further investigation into its broader therapeutic applications.Explore the study’s methodology and unpack the implications of these early findings. Learn about the potential benefits of IVIG and its influence on cancer rates. Discover what’s next …
IVIG Therapy May Reduce Cancer Risk in Neuromuscular Patients
intravenous immunoglobulin, or IVIG, a common treatment for autoimmune and neurological conditions, may also reduce cancer risk, according too a new study in Frontiers. Researchers examined the potential role of IVIG therapy in patients with myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
IVIG is a well-established treatment for various autoimmune diseases, neurologic diseases, infections and immunodeficiencies. Its effectiveness has been demonstrated in managing MG and CIDP. though,its high cost and limited accessibility pose challenges. Scientists are exploring IVIG’s potential in treating other conditions, including cancers.
Previous research hinted at IVIG’s antineoplastic effects through its influence on IL-12 and NK cell activity. Some reports linked IVIG to tumor stability and longer survival in melanoma patients.However, the evidence remains “scattered and inconclusive,” prompting researchers to investigate IVIG’s impact on cancer incidence in MG and CIDP patients.
The study compared cancer rates in MG and CIDP patients undergoing chronic IVIG therapy with those receiving other immunosuppress